SWAV - Shockwave Medical, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Santa Clara,
United States
Type: Equity
SWAV price evolution
SWAV
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $281.67 | $328.42 | $498.11 | $141.46 |
| Short term investments | $747.56 | $662.13 | $419.23 | $117.13 |
| Net receivables | $124.44 | $114.55 | $98.82 | $96.56 |
| Inventory | $111.22 | $107.59 | $97.18 | $92.09 |
| Total current assets | $1275.35 | $1225.26 | $1128.54 | $456.36 |
| Long term investments | $2.36 | $1.64 | $1.81 | $2.54 |
| Property, plant & equipment | $113.61 | $98.63 | $92.38 | $90.92 |
| Goodwill & intangible assets | $131.53 | $132.43 | $133.56 | $134.48 |
| Total noncurrent assets | $368.4 | $341.3 | $345.42 | $330.24 |
| Total investments | $749.91 | $663.77 | $421.04 | $119.67 |
| Total assets | $1643.75 | $1566.56 | $1473.96 | $786.6 |
| Current liabilities | ||||
| Accounts payable | $9.84 | $8.87 | $6.87 | $12.87 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $92.33 | $104.2 | $78.2 | $80.22 |
| Long term debt | $773.15 | $766.97 | $763.28 | $57.47 |
| Total noncurrent liabilities | $799.66 | $793.68 | $794.51 | $89.47 |
| Total debt | $773.15 | $766.97 | $763.28 | $57.47 |
| Total liabilities | $891.99 | $897.89 | $872.71 | $169.69 |
| Shareholders' equity | ||||
| Retained earnings | $165.81 | $110.47 | $66.16 | $31.17 |
| Other shareholder equity | -$0.11 | $0.29 | -$0.15 | -$0.39 |
| Total shareholder equity | $751.76 | $668.68 | $601.25 | $616.91 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $328.42 | $156.59 | $89.21 | $50.42 |
| Short term investments | $662.13 | $147.91 | $111.77 | $151.93 |
| Net receivables | $114.55 | $71.37 | $37.44 | $11.69 |
| Inventory | $107.59 | $75.11 | $42.98 | $29.86 |
| Total current assets | $1225.26 | $459.26 | $285.9 | $246.3 |
| Long term investments | $1.64 | $3.51 | $5.99 | |
| Property, plant & equipment | $98.63 | $80.52 | $51.86 | $23.93 |
| Goodwill & intangible assets | $132.43 | |||
| Total noncurrent assets | $341.3 | $186.83 | $59.78 | $25.74 |
| Total investments | $663.77 | $151.42 | $117.76 | $151.93 |
| Total assets | $1566.56 | $646.09 | $345.68 | $272.04 |
| Current liabilities | ||||
| Accounts payable | $8.87 | $6.72 | $3.52 | $1.47 |
| Deferred revenue | ||||
| Short long term debt | $5.5 | $3.3 | ||
| Total current liabilities | $104.2 | $63.37 | $51.63 | $25.58 |
| Long term debt | $766.97 | $59.13 | $39.95 | $20.81 |
| Total noncurrent liabilities | $793.68 | $71.4 | $52.22 | $20.81 |
| Total debt | $766.97 | $59.13 | $45.45 | $24.11 |
| Total liabilities | $897.89 | $134.77 | $103.85 | $46.39 |
| Shareholders' equity | ||||
| Retained earnings | $110.47 | -$36.81 | -$252.81 | -$243.67 |
| Other shareholder equity | $0.29 | -$0.87 | -$0.2 | $0.01 |
| Total shareholder equity | $668.68 | $511.32 | $241.83 | $225.65 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $218.81 | $202.98 | $186.02 | $180.16 |
| Cost of revenue | $28.21 | $25.32 | $24.51 | $24.49 |
| Gross Profit | $190.6 | $177.66 | $161.51 | $155.67 |
| Operating activities | ||||
| Research & development | $44.47 | $42.32 | $39.53 | $36.83 |
| Selling, general & administrative | $103.72 | $92.06 | $78.36 | $86.47 |
| Total operating expenses | $148.19 | $134.38 | $117.88 | $123.3 |
| Operating income | $42.41 | $43.28 | $43.62 | $32.37 |
| Income from continuing operations | ||||
| EBIT | $52.94 | $58.41 | $47.59 | $33.81 |
| Income tax expense | -$5.35 | $11.15 | $10.09 | $4.14 |
| Interest expense | $2.94 | $2.95 | $2.51 | $0.81 |
| Net income | ||||
| Net income | $55.35 | $44.3 | $34.99 | $28.86 |
| Income (for common shares) | $55.35 | $44.3 | $34.99 | $28.86 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $730.23 | $489.73 | $237.15 | $67.79 |
| Cost of revenue | $95.39 | $65 | $41.44 | $20.99 |
| Gross Profit | $634.84 | $424.74 | $195.71 | $46.8 |
| Operating activities | ||||
| Research & development | $145.65 | $81.68 | $50.54 | $36.93 |
| Selling, general & administrative | $330.1 | $218.92 | $146.03 | $75.53 |
| Total operating expenses | $475.75 | $300.6 | $196.58 | $112.46 |
| Operating income | $159.09 | $124.13 | -$0.87 | -$65.66 |
| Income from continuing operations | ||||
| EBIT | $181.19 | $122.71 | -$7.74 | -$64.41 |
| Income tax expense | $27 | -$95.17 | $0.3 | $0.08 |
| Interest expense | $6.91 | $1.89 | $1.1 | $1.21 |
| Net income | ||||
| Net income | $147.28 | $216 | -$9.14 | -$65.7 |
| Income (for common shares) | $147.28 | $216 | -$9.14 | -$65.7 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | $55.35 | $44.3 | $34.99 | $28.86 |
| Operating activities | ||||
| Depreciation | $4 | $3.84 | $3.84 | $3.38 |
| Business acquisitions & disposals | -$94.41 | |||
| Stock-based compensation | $22.94 | $21.81 | $18.41 | $17.05 |
| Total cash flows from operations | $35.84 | $71.7 | $50.65 | $39.74 |
| Investing activities | ||||
| Capital expenditures | -$8.39 | -$8.12 | -$6.54 | -$8.75 |
| Investments | -$76.06 | -$234.14 | -$299.34 | $19.39 |
| Total cash flows from investing | -$84.45 | -$242.26 | -$305.88 | -$83.77 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.02 | $0.19 | $3.6 | $0.4 |
| Net borrowings | -$0.35 | $609.43 | -$80 | |
| Total cash flows from financing | $5.01 | -$0.16 | $613 | -$95.84 |
| Effect of exchange rate | -$3.17 | $1.1 | -$0.77 | -$0.32 |
| Change in cash and equivalents | -$46.78 | -$169.62 | $357 | -$140.19 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $147.28 | $216 | -$9.14 | -$65.7 |
| Operating activities | ||||
| Depreciation | $13.52 | $7.9 | $5.54 | $3.35 |
| Business acquisitions & disposals | -$94.41 | |||
| Stock-based compensation | $73.23 | $44.89 | $27.26 | $10.35 |
| Total cash flows from operations | $196.05 | $117.73 | $15.04 | -$71.18 |
| Investing activities | ||||
| Capital expenditures | -$30.59 | -$25.13 | -$12.44 | -$11.52 |
| Investments | -$500.72 | -$37.02 | $38.85 | -$95.95 |
| Total cash flows from investing | -$625.73 | -$62.15 | $26.42 | -$107.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.6 | $7.05 | $5.89 | $89.48 |
| Net borrowings | $609.08 | $5.97 | $2.15 | |
| Total cash flows from financing | $600.4 | $13 | -$2.45 | $90.03 |
| Effect of exchange rate | $0.8 | -$1.15 | ||
| Change in cash and equivalents | $171.52 | $67.43 | $39 | -$88.62 |
News
|
12 Best Large-Cap Growth ETFs
Insider Monkey via Yahoo Finance
7 May 2024
|
|
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
Zacks
7 May 2024
|
|
Beyond the Balance Sheet: What SWOT Reveals About Shockwave Medical Inc (SWAV)
GuruFocus.com via Yahoo Finance
7 May 2024
|
|
Earnings will drive the market next week — what we expect from 2 portfolio stocks
CNBC
4 May 2024
|
|
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
Zacks · via Yahoo Finance
30 Apr 2024
|
|
Shockwave Medical (SWAV) Rose on an Acquisition News and Solid Financial Result
Insider Monkey via Yahoo Finance
24 Apr 2024
|
|
10 Best Performing Biotech ETFs in 2024
Insider Monkey via Yahoo Finance
22 Apr 2024
|
|
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
Zacks via Yahoo Finance
22 Apr 2024
|
|
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
Zacks via Yahoo Finance
22 Apr 2024
|
|
11 Best Low Price Pharma Stocks To Invest In
Insider Monkey via Yahoo Finance
21 Apr 2024
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $787.97M |
|---|---|
| EBITDA | $207.81M |
| EBIT | $192.75M |
| Net Income | $163.50M |
| Revenue Q/Q | 35.85% |
| Revenue Y/Y | 41.42% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 11.95% |
| ROE | 24.79% |
| Debt/Equity | 1.34 |
|---|---|
| Net debt/EBITDA | 2.94 |
| Current ratio | 13.81 |
| Quick ratio | 12.61 |